Safety and immunogenicity of a second dose of an investigational maternal trivalent Group B streptococcus vaccine in non-pregnant women 4-6 years after a first dose: results from a phase 2 trial.
Maternal immunization against Group B streptococcus (GBS) could protect infants from invasive GBS disease. Additional doses in subsequent pregnancies may be needed. This study evaluated the safety and immunogenicity of a second dose of an investigational trivalent CRM197-glycoconjugate GBS vaccine (targeting serotypes Ia/Ib/III), administered to non-pregnant women 4-6 years post-dose 1. Healthy women either previously vaccinated with one dose of trivalent GBS vaccine 4-6 years before enrollment (n=53) or never GBS-vaccinated (n=27) received a single trivalent GBS vaccine injection. Adverse events (AEs) were recorded. Serotype-specific (Ia/Ib/III) anti-GBS antibodies were measured by multiplex immunoassay pre-vaccination and 30/60 days post-vaccination. AEs were reported with similar rates after a first or second dose. No serious AEs were reported. 92%-98% of previously GBS-vaccinated women had anti-GBS concentrations exceeding an arbitrary threshold of 8 µg/mL for each serotype 60 days post-dose 2, versus 36%-56% post-dose 1 in previously non-GBS-vaccinated women. 90%-98% of previously GBS-vaccinated women with undetectable baseline (pre-dose 1) anti-GBS levels reached this threshold post-dose 2. For each serotype, anti-GBS geometric mean concentrations (GMCs) 30/60 days post-dose 2 in previously GBS-vaccinated women were ≥200-fold higher than baseline GMCs. Among women with undetectable baseline anti-GBS levels, post-dose 2 GMCs in previously GBS-vaccinated women exceeded post-dose 1 GMCs in previously non-GBS-vaccinated women (≥7-fold). A second trivalent GBS vaccine dose administered 4-6 years post-dose 1 was immunogenic with a favorable safety profile. Women with undetectable pre-existing anti-GBS concentrations may benefit from a sufficiently spaced second vaccine dose.